EGFR and non-small cell lung carcinoma: In patients with NSCLC with mutated epidermal growth factor receptor (EGFR), EGFR-tyrosine kinase inhibitors, including gefitinib and erlotinib, have enabled a significantly longer survival time of about 30 months and higher response rates of 70% to 80% [7,8].